暂无推荐供应商。我要出现这里
化源商城直购
[1]. Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. Front Immunol. 2022;13:1073777.
[2]. Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Front Med (Lausanne). 2023;9:959289.